Nintedanib Eignapharma (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR, and PDGFR—thereby reducing fibroblast proliferation, new blood‑vessel formation, and the deposition of scar tissue. This dual antifibrotic and anti‑angiogenic activity helps slow disease progression in the lungs and can limit tumor growth.

The specific dose and dosing schedule of Nintedanib Eignapharma are determined by the prescribing physician based on the patient’s condition, weight, renal and hepatic function, and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Nintedanib in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To request Nintedanib Eignapharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nintedanib differs from other antifibrotics such as pirfenidone by targeting a broader range of tyrosine kinases (VEGFR, FGFR, PDGFR). This broader inhibition may provide additional benefit in certain fibrotic pathways, but the safety profile and tolerability can vary. Choice of therapy should be individualized by the treating physician.

Nintedanib Eignapharma should be stored at temperatures below 25 °C, in the original packaging, protected from moisture and direct light. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Nintedanib Eignapharma is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets (or capsules, depending on the specific presentation) are swallowed whole with a glass of water. Patients should follow the dosing instructions provided by their prescriber.

The most serious risks include severe liver injury, major bleeding events, cardiovascular complications such as myocardial infarction, gastrointestinal perforation, and rare cases of pulmonary hypertension. Patients should be monitored regularly for signs of these adverse events and report any concerning symptoms promptly.

Nintedanib is contraindicated in patients with severe hepatic impairment (Child‑Pugh C), those with known hypersensitivity to the drug or its excipients, and individuals who are currently experiencing significant bleeding or have uncontrolled hypertension. The prescriber should evaluate each patient’s medical history before initiating therapy.